疏肝健脾方药对NASH大鼠心脏舒张功能及炎症因子的影响  

Effect of Shuganjianpifang on cardiac diastolic function and inflammatory factors in rats with nonalcoholic steatosis hepatitis

作　　者：王文晶[1] 杨钦河[1] 冯高飞[1] 王彦平[1] 何秀敏[1] 张玉佩[1] 杨雪萍 闫海震[1] 黄进[1] 李光秋[1] 赵亚凤[1] 杨晓蕾[1] 沈灿宏[1] 

机构地区：[1]暨南大学医学院,广东省广州市510632 [2]河南省偃师市人民医院消化内科,河南省偃师市471900

出　　处：《世界华人消化杂志》2011年第25期2615-2622,共8页World Chinese Journal of Digestology

基　　金：国家自然科学基金资助项目;No.30973694;国家大学生创新性实验计划基金资助项目;No.091055930~~

摘　　要：目的:探讨疏肝健脾方药对非酒精性脂肪性肝炎(nonalcoholic steatosis hepatitis,NASH)合并心脏舒张功能不全大鼠干预的作用机制.方法:采用高脂饲料喂养复制NASH大鼠实验模型,各药物组分别灌服疏肝方、健脾方和综合方(疏肝方和健脾方的合方)进行干预,16wk后用Visual Sonics Vevo770TM高分辨率小动物超声诊断仪检测大鼠心脏每搏输出量(SV)、左心室射血分数(LVEF)、左心室短轴缩短率(LVFS)用以评价大鼠心脏收缩功能,检测E/A比值用以评价大鼠心脏舒张功能.然后处死大鼠,腹主动脉采血,用全自动生化分析仪检测血脂及肝脂的含量;常规HE染色观察肝组织病理变化;ELISA法检测血清TNF-α和IL-6的水平.结果:肝组织病理染色提示大鼠NASH造模成功;与正常对照组相比,模型组大鼠心脏舒张功能明显降低(1.59±0.24vs1.03±0.13,P<0.01),血清TNF-α和IL-6含量显著升高(13.57±4.64vs28.26±8.60;59.28±71.53vs132.81±74.22,P<0.01、0.05),血清TC、LDL及肝组织TC、TG含量也明显升高(1.42±0.29vs3.82±0.91;0.30±0.11vs0.81±0.27;0.90±0.14vs11.86±1.29;0.75±0.38vs6.17±1.83,均P<0.01),SV、LVEF、LVFS均比正常组有不同程度的下降;各药物组大鼠心脏舒张功能较模型组有显著改善,以健脾高剂量组、综合方高剂量组的E/A比值升高最为明显(1.26±0.23vs1.03±0.13;1.35±0.15vs1.03±0.13,均P<0.01);各药物组大鼠血清TNF-α及IL-6含量与模型组相比明显下降,以综合方高剂量组的血清下降最为明显(15.07±6.00vs28.26±8.60;67.72±44.24vs132.81±74.22,P<0.01,0.05);脂质代谢检测以合方高剂量组的血清TG及肝组织TC、TG下降最为明显(0.45±0.14vs0.83±0.26;9.17±1.02vs11.86±1.29;2.54±0.74vs6.17±1.83,均P<0.01).结论:NASH大鼠伴有心脏舒张功能不全,疏肝健脾方药抗NASH及改善NASH大鼠心脏舒张功能可能与其降低血清中炎症因子TNF-α和IL-6的水平有关.AIM： To investigate the effect of Shuganjianpifang on cardiac diastolic dysfunction in rats with nonalcoholic steatosis hepatitis （NASH） and to explore the possible mechanisms involved.METHODS： NASH was induced in rats by feeding a high-fat diet. Rats were divided into eight groups： normal control group, model group, high- and low-dose Ganfang, Pifang and Shuganjianpifang groups. After treatment for 16 weeks, stroke volume （SV）, left ventricular ejection fraction （LVEF）, and left ventricular diameter （LVFS） were measured to evaluate cardiac systolic function, and E/A ratio was calculated to evaluate cardiac diastolic function. Serum levels of TC, TG, HDL, and LDL, as well as TC and TG in the hepatic homogenate were detected using an automatic biochemical analyzer. Histopathological changes were observed after HE staining. Serum TNF-α and IL-6 levels were determined by enzyme-linked immunosorbent assay （ELISA）.RESULTS： Compared to the normal group, rats in the model group revealed medium fatty degeneration in hepatocytes, declined cardiac diastolic function （1.59 ± 0.24 vs 1.03 ± 0.13, P 〈 0.01）, increased serum levels TNF-α （13.57 ±4.64 vs 28.26 ± 8.60, P 〈 0.01）, IL-6 （59.28 ± 71.53 vs 132.81 ± 74.22, P 〈 0.05）, TC （1.42 ± 0.29 vs 3.82 ± 0.91, P 〈 0.01）, LDL （0.30 ± 0.11 vs 0.81 ± 0.27, P 〈 0.01） and hepatic levels of TC （0.90 ± 0.14 vs 11.86 ± 1.29, P 〈 0.01） and TG （0.75 ± 0.38 vs 6.17 ± 1.83, P 〈 0.01）, and decreased SV,LVEF and LVFS in the model group. Compared to the model group, cardiac diastolic function was significantly improved in rats in each treatment group, especially prominent in the high- dose Shuganjianpifang group （1.26 ± 0.23 vs 1.03 ± 0.13; 1.35 ± 0.15 vs 1.03 ± 0.13, both P 〈 0.01）. In addition, the levels of blood and liver lipids and serum TNF-α and IL-6 decreased in each treatment group, especially in the high-dose Shuganjianpifang group （0.45 ± 0.14 vs 0.83 -± 0.26; 9.17 ± 1.02 vs 11.86 �

关 键 词：非酒精性脂肪性肝炎 心脏舒张功能 炎症因子 高分辨率小动物超声诊断仪 大鼠 

分 类 号：R285.5[医药卫生—中药学]